中國金融租賃(02312.HK)供股獲超額認購約31.8%
格隆匯2月16日丨中國金融租賃(02312.HK)發佈公吿,由於包銷協議載列的所有條件均已達成,且包銷商並未於最後終止時限之前終止包銷協議,因此供股於2024年2月9日下午4時30分成為無條件。
總計而言,已接獲14份以暫定配額通知書及額外申請表格提交的有效接納及申請,涉及合共2.29億股供股股份,相當於供股股份總數約131.8%。
根據上述結果,供股獲超額認購5510萬股供股股份,相當於供股股份總數約31.8%。
供股籌得所得款項總額約為20.8百萬港元,而扣除開支後的供股所得款項淨額約為19.4百萬港元。
繳足股款供股股份預期將於2024年2月20日上午九時正在聯交所開始買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.